Coherus BioSciences (CHRS) Reports Q3 Loss, Tops Revenue Estimates
Portfolio Pulse from
Coherus BioSciences (CHRS) reported a Q3 loss of $0.01 per share, which was better than the expected loss of $0.10 per share. This is an improvement from the $0.27 per share loss reported a year ago.
November 06, 2024 | 11:30 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Coherus BioSciences reported a smaller-than-expected Q3 loss of $0.01 per share, beating the Zacks Consensus Estimate of a $0.10 loss. This marks an improvement from the previous year's $0.27 loss per share.
The better-than-expected earnings report is likely to have a positive impact on Coherus BioSciences' stock price in the short term. The improvement from last year's loss also adds to the positive sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100